Access Program Information
<p>This is a phase III B, prospective, interventional, open-label, single-arm, multicenter study to provide <strong>regorafenib</strong> to subjects diagnosed with <strong>metastatic colorectal cancer</strong> who have failed after standard therapy and for whom no therapy alternatives exist, in the time between positive results and approval / availability on the market, and to collect safety data for regorafenib until market access.</p>
<p><strong>Regorafenib</strong> is an oral (i.e. taken by mouth) multi-targeted kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, regorafenib may stop cancer growth.</p>
<p>The growth of the tumor may be decreased by preventing these specific proteins from functioning. The primary endpoint of this study will be safety.</p>